Market Research Industry Reports

Soligenix Inc (SNGX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development of products for the treatment of serious inflammatory diseases and biodefense counter measures. It develops biotherapeutics for the treatment of orphan diseases such as cutaneous T-cell lymphoma, pediatric Crohns disease, oral mucositis and acute radiation enteritis. It develops proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the treatment of gastrointestinal disorders that are characterized by high inflammation, including pediatric Crohns disease, acute radiation enteritis and oral mucositis. The company has active development programs for RiVax, a ricin toxin vaccine; VeloThrax, an anthrax vaccine; and OrbeShield, a gastrointestinal acute radiation syndrome therapeutic. These vaccine programs are supported by ThermoVax, a heat stabilization technology. Soligenix is headquartered in Princeton, New Jersey, the US.

Soligenix Inc (SNGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Venture Financing 15
Soligenix Raises USD2 Million in Venture Financing 15
Partnerships 16
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
Licensing Agreements 23
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Equity Offering 27
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 27
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 29
Soligenix Raises USD3.2 Million in Public Offering of Shares 30
Soligenix Raises USD2 Million in Private Placement of Shares 31
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 32
Soligenix to Raise USD12 Million in Private Placement of Shares 34
Soligenix Raises USD2.3 Million in Public Offering of Shares 35
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 37
Soligenix Completes Private Placement Of Units For US$7 Million 38
Soligenix Inc - Key Competitors 39
Soligenix Inc - Key Employees 40
Soligenix Inc - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
May 11, 2018: Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results 42
Mar 15, 2018: Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results 43
Nov 06, 2017: Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results 44
Aug 11, 2017: Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results 45
May 11, 2017: Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results 47
Mar 27, 2017: Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results 49
Product Approvals 51
Feb 02, 2017: Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency 51
Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients 52
Clinical Trials 53
Jun 04, 2018: Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia 53
Jan 02, 2018: Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis 55
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference 57
Oct 24, 2017: Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium 58
Oct 05, 2017: Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology 60
Jul 27, 2017: Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 62
Jun 19, 2017: Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference 64
May 18, 2017: Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 66
May 03, 2017: Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 68
Other Significant Developments 69
Jan 25, 2018: Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials 69
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List Of Tables

List of Tables
Soligenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Soligenix Raises USD2 Million in Venture Financing 15
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 27
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 29
Soligenix Raises USD3.2 Million in Public Offering of Shares 30
Soligenix Raises USD2 Million in Private Placement of Shares 31
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 32
Soligenix to Raise USD12 Million in Private Placement of Shares 34
Soligenix Raises USD2.3 Million in Public Offering of Shares 35
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 37
Soligenix Completes Private Placement Of Units For US$7 Million 38
Soligenix Inc, Key Competitors 39
Soligenix Inc, Key Employees 40
Soligenix Inc, Subsidiaries 41

List Of Figures

List of Figures
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Soligenix Inc (SNGX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Soligenix Inc (Soligenix) is a late-stage biopharmaceutical company which focuses on the development of products for the treatment of serious inflammatory diseases and biodefense counter measures. It develops biotherapeutics for

USD 250View Report

Soligenix Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Soligenix Inc Company Profile is a detailed strategic and analytical report on Soligenix Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Soligenix Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Soligenix Inc Company Profile is a detailed strategic and analytical report on Soligenix Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200View Report

Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review

Soligenix Inc (SNGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData

USD 125View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2018
No. of Pages :72
Country :United States of America
Category :Company Profiles
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube